Sign In
Buy VXRT
$0.519
-0.0111 (-2.09%)
At Close: Jun 23, 2026
Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript
07:03pm, Thursday, 14'th Mar 2024
Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
04:01pm, Thursday, 14'th Mar 2024
Significant progress made in preparing for a Phase 2b study evaluating Vaxart's oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
08:00am, Thursday, 07'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended Dece
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
08:00am, Wednesday, 06'th Mar 2024
Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif.
VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy?
01:00pm, Monday, 26'th Feb 2024
Does VAXART, INC. (VXRT) have what it takes to be a top stock pick for momentum investors?
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
10:11am, Friday, 23'rd Feb 2024
Amid the broad-market rally, shares of Equillium (EQ), Phunware (PHUN), Super Micro Computer (SMCI), Vaxart (VXRT) and Dianthus Therapeutics (DNTH) have more than doubled this year.
VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?
10:56am, Tuesday, 20'th Feb 2024
VAXART, INC. (VXRT) reached a significant support level, and could be a good pick for investors from a technical perspective.
— Data served as foundation for current vaccine candidate for planned Phase 2 research — Vaxart vaccine candidates elicited strong antigen-specific serum IgG and IgA with neutralizing activi
- 10,000-subject Phase 2b study would evaluate Vaxart's next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator -
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
09:25am, Tuesday, 16'th Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for the
Vaxart, Inc. Announces Management Change
09:22am, Tuesday, 16'th Jan 2024
Chief Executive Officer Andrei Floroiu Resigns Chair Michael J. Finney, Ph.D.
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
08:00am, Thursday, 21'st Dec 2023
On track to report topline data by the end of 2024 SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed enrollment and dosin
Vaxart, Inc. (VXRT) Q3 2023 Earnings Call Transcript
07:37pm, Thursday, 02'nd Nov 2023
Vaxart, Inc. (NASDAQ:VXRT ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Andrei Floroiu - President and CEO James Cummings - Chief Medical Officer Phil Lee - CFO B
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
04:01pm, Thursday, 02'nd Nov 2023
Norovirus challenge study topline results indicate the potential of Vaxart's oral pill vaccine candidate to reduce rates of norovirus infection, norovirus acute gastroenteritis and viral shedding
Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19
08:00am, Wednesday, 11'th Oct 2023
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief
